by The India Immuno-Oncology Drugs Market is estimated to be valued at US$ 338.98 Mn or Million in 2023 and is expected to exhibit a CAGR of 13.% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Immuno-oncology drugs work by enhancing the body’s natural defenses to allow the immune system to fight cancer. These drugs help white blood cells called lymphocytes (a type of white blood cell) to recognize and destroy cancer cells. This is advantageous as it empowers the body’s own immune defenses for anticancer activity in a targeted and safe manner.
Market key trends:
One of the key trends in the India immuno-oncology drugs market is the growing adoption of combination therapies. Combination therapies involve using two or more drugs that work through different mechanisms. This helps improve response rates and outcomes compared to single-agent therapies. Some of the widely adopted combination strategies in immuno-oncology include combining immune checkpoint inhibitors with other immune checkpoint inhibitors or chemotherapy. For instance, the combination of Opdivo (nivolumab) and Yervoy (ipilimumab) has been approved for treating metastatic melanoma and renal cell carcinoma.
Segment Analysis
The India immuno-oncology drugs market is segmented into checkpoint inhibitors, monoclonal antibodies, cytokine-based immunotherapy, cancer vaccines, cell therapies, and others. Among these, checkpoint inhibitors dominate the market and accounted for over 35% share in 2022. Checkpoint inhibitors halt mechanisms by which cancer cells evade the immune system. Drugs like Merck & Co.’s Keytruda target programmed death receptor 1 (PD-1) and are widely prescribed for lung cancer and melanoma indications.
Key Takeaways
India Immuno-Oncology Drugs Market Demand is expected to witness high growth, exhibiting CAGR of 13% over the forecast period, due to increasing incidence of cancer cases and rising acceptance of targeted therapies.
Regional analysis
Southern region dominated the India immuno-oncology drugs market in 2022 and is expected to grow at a high rate during the forecast period. This is attributed to increasing cancer awareness programs organized by both government and private organizations and rising healthcare expenditure in this region.
Key players
Key players operating in the India immuno-oncology drugs market are Amgen Inc., F. Hoffmann-La Roche AG., Intas Pharmaceuticals Ltd., AstraZeneca plc, Mylan N.V., Dr. Reddy’s Laboratories, Bristol – Myers Squibb, Merck & Co., Inc., BIOCAD-Biotechnology company, Reliance Life Sciences, Biocon Limited, and Hetero Drugs Limited.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
